NCM · Medical - Devices

NXL (NXL) Stock

$0.35 +0.91% NCM: NXL Healthcare

Valuation

MetricValue
Price$0.35
Market Cap$7.60M
P/E Ratio-1.13
P/B Ratio1.79
P/S Ratio29.80
EPS (TTM)$-0.31
52-Week High$2.00
52-Week Low$0.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-2.22%
ROA-1.18%
ROCE-200.00%
Gross Margin-1.03%
Operating Margin-30.84%
Net Margin-30.23%
Debt/Equity0.00
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$1.0M$0$0$0
Operating Profit$-6.0M$-2.0M$-6.0M$-8.0M$-8.0M
Net Profit$-6.0M$-2.0M$-5.0M$-8.0M$-8.0M
EPS$-0.83$-0.23$-0.63$-0.83$-0.50
Op Margin-4177.7%-138.7%-5143.5%-4596.1%-2781.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.0M$7.0M$4.0M$4.0M$5.0M
Total Liabilities$2.0M$2.0M$0$1.0M$1.0M
Cash$1.0M$0$1.0M$1.0M$1.0M
Borrowings$1.0M$1.0M$0$0$0

Latest News

NexaLine Technology Registers 1.2 Million Shares for Resale MT Newswires · Jun 29, 2026 Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform GlobeNewswire · Jun 23, 2026 Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life GlobeNewswire · Jun 16, 2026 Nexalin Study Shows Strong Anxiety and Depression Response in Brazil Trial MT Newswires · Jun 10, 2026 Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan. GlobeNewswire · Jun 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-1.0M$-2.0M$-4.0M$-4.0M$-5.0M
Investing Cash Flow$0$-7.0M$4.0M$-1.0M$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$1.0M$0$0$0$0
Free Cash Flow$-1.0M$-2.0M$-4.0M$-4.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-64.46%
Quick Ratio3.85
Interest Coverage—
Return 1Y-54.02%
Return 3Y-42.45%
Return 5Y—

Ownership

Insiders Held10.50%
Institutions Held4.89%
Institutions Float Held5.46%
Institutional HolderSharesReport Date
Peak6 LLC384,4602026-03-31
Geode Capital Management, LLC247,0372026-03-31
Vanguard Capital Management LLC126,5362026-03-31
Vanguard Fiduciary Trust Co51,3862026-03-31
State Street Corporation32,3002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLGN $0.27 -9.04% -0.48 $3.54M 0.00%
ENLV $2.12 -5.36% 0.03 $35.68M 0.00%
HBIO $6.10 +0.16% -0.42 $27.51M 0.00%
IINNInspira Technologies OXY B.H.N. Ltd. $1.26 -5.97% -2.80 $30.34M 0.00%
MODD $2.39 +15.46% -0.22 $5.04M 0.00%

About NXL

NXL is led by CEO Mark White, employs 6 people, headquartered in US, publicly traded since 2022.

NXL stock trades at $0.35 with a market capitalization of $7.60M. The stock is valued at a price-to-earnings (P/E) ratio of -1.13, price-to-book of 1.79, price-to-sales of 29.80. Over the past 52 weeks the stock has ranged between $0.30 and $2.00, and currently trades 82.5% below its 52-week high.

On profitability, NXL generates a return on equity (ROE) of -2.22%, return on capital employed of -200.00%, an operating margin of -30.84%, a net profit margin of -30.23%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides